Imaging of Tumor Hypoxia With 18F-EF5 PET/MRI in Cervical Cancer.
Journal
Clinical nuclear medicine
ISSN: 1536-0229
Titre abrégé: Clin Nucl Med
Pays: United States
ID NLM: 7611109
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
pubmed:
8
10
2021
medline:
9
11
2021
entrez:
7
10
2021
Statut:
ppublish
Résumé
The aim of this study was to evaluate the distribution of hypoxia using 18F-EF5 as a hypoxia tracer in cervical cancer patients with PET/MRI. We investigated the association between this 18F-EF5-PET tracer and the immunohistochemical expression of endogenous hypoxia markers: HIF1α, CAIX, and GLUT1. Nine patients with biopsy-proven primary squamous cell cervix carcinoma (FIGO 2018 radiological stages IB1-IIIC2r) were imaged with dual tracers 18F-EF5 and 18F-FDG using PET/MRI (Int J Gynaecol Obstet. 2019;145:129-135). 18F-EF5 images were analyzed by calculating the tumor-to-muscle ratio to determine the hypoxic tissue (T/M ratio >1.5) and further hypoxic subvolume (HSV) and percentage hypoxic area. These 18F-EF5 hypoxic parameters were correlated with the size and localization of tumors in 18F-FDG PET/MRI and the results of hypoxia immunohistochemistry. All primary tumors were clearly 18F-FDG and 18F-EF5 PET positive and heterogeneously hypoxic with multiple 18F-EF5-avid areas in locally advanced cancer and single areas in clinically stage I tumors. The location of hypoxia was detected mainly in the periphery of tumor. Hypoxia parameters 18F-EF5 max T/M ratio and HSV in primary tumors correlated independently with the advanced stage (P = 0.036 and P = 0.040, respectively), and HSV correlated with the tumor size (P = 0.027). The location of hypoxia in 18F-EF5 imaging was confirmed with a higher hypoxic marker expression HIF1α and CAIX in tumor fresh biopsies. The 18F-EF5 imaging has promising potential in detecting areas of tumor hypoxia in cervical cancer.
Identifiants
pubmed: 34619699
doi: 10.1097/RLU.0000000000003914
pii: 00003072-202112000-00002
doi:
Substances chimiques
Fluorine Radioisotopes
0
Hydrocarbons, Fluorinated
0
Radiopharmaceuticals
0
Etanidazole
30DKA3Q1HL
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
952-957Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: The authors declare no conflicts of interest. This work was supported by the Finnish Government (research funds from specified government transfers).
Références
Challapalli A, Carroll L, Aboagye EO. Molecular mechanisms of hypoxia in cancer. Clin Transl Imaging . 2017;5:225–253.
Wouters BG, Weppler SA, Koritzinsky M, et al. Hypoxia as a target for combined modality treatments. Eur J Cancer . 2002;38:240–257.
Nguyen NC, Beriwal S, Moon CH, et al. Diagnostic value of FDG PET/MRI in females with pelvic malignancy—a systematic review of the literature. Front Oncol . 2020;10:519440.
Koch CJ, Scheuermann JS, Divgi C, et al. Biodistribution and dosimetry of 18 F-EF5 in cancer patients with preliminary comparison of 18 F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging . 2010;37:2048–2059.
Dolbier WR, Li AR, Koch CJ, et al. 18 F-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot . 2001;54:73–80.
Komar G, Seppänen M, Eskola O, et al. 18 F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med . 2008;49:1944–1951.
Komar G, Lehtiö K, Seppänen M, et al. Prognostic value of tumour blood flow, 18 F-EF5 and 18 F-FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy. Eur J Nucl Med Mol Imaging . 2014;41:2042–2050.
Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev . 2007;26:225–239.
Eskola O, Grönroos TJ, Forsback S, et al. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer 18 F-EF5. Mol Imaging Biol . 2012;14:205–212.
Silén J, Högel H, Kivinen K, et al. Uptake of 18 F-EF5 as a tracer for hypoxic and aggressive phenotype in experimental head and neck squamous cell carcinoma. Transl Oncol . 2014;7:323–330.
Evans SM, Hahn S, Pook DR, et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res . 2000;60:2018–2024.
Zegers CML, van Elmpt W, Reymen B, et al. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using 18 F-HX4 and 18 F-FDG PET/CT imaging. Clin Cancer Res . 2014;20:6389–6397.
Dehdashti F, Grigsby PW, Lewis JS, et al. Assessing tumor hypoxia in cervical cancer by PET with 60 Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med . 2008;49:201–205.
Vercellino L, Groheux D, Thoury A, et al. Hypoxia imaging of uterine cervix carcinoma with 18 F-FETNIM PET/CT. Clin Nucl Med . 2012;37:1065–1068.
Lyng H, Malinen E. Hypoxia in cervical cancer: from biology to imaging. Clin Transl Imaging . 2017;5:373–388.
Grigsby PW, Malyapa RS, Higashikubo R, et al. Comparison of molecular markers of hypoxia and imaging with 60 Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol . 2007;9:278–283.
Han K, Shek T, Vines D, et al. Measurement of tumor hypoxia in patients with locally advanced cervical cancer using positron emission tomography with 18 F-Fluoroazomyin arabinoside. Int J Radiat Oncol Biol Phys . 2018;102:1202–1209.